Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological Malignancies and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SF3B1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SF3B1 (WT & K700E Mutant) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View SF3B1 Products |
| Gene Delivery | SF3B1 Lentivirus (WT & K700E) Full-length ORF for stable cell line construction and splicing assays. |
View SF3B1 Products |
| Benchmark Ab | Anti-SF3B1 Recombinant Antibody Recombinant positive control for Western Blot and IP. |
View SF3B1 Products |
| Validator | SF3B1 siRNA Set For knockdown verification and target validation. |
View SF3B1 Products |
| Related Target A | SF3B2 Essential subunit of the SF3b complex; critical for off-target and selectivity screening. |
View SF3B2 Products |
| Related Target B | SRSF2 Co-mutated splicing factor in myelodysplastic syndromes (MDS); key node for combination study. |
View SRSF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs. WT Selectivity Screening | Recombinant SF3B1 WT and K700E mutant proteins available with >95% purity and verified sequence accuracy. |
| Complex Reconstitution for SPR/FP | Sf9/Baculovirus or mammalian-expressed SF3B1 preserving native post-translational states. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control detection reagents. |
| False Positives in Splicing Modulation | Validated siRNA sets included for target-specific knockdown verification. |
Live SF3B1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SF3B1 therapeutics is intensifying, with major players shifting focus from traditional pan-splicing inhibitors to mutant-selective small molecule modulators. As first-generation splicing modulators (such as H3B-8800) pave the way in clinical trials for myeloid neoplasms, the next wave of R&D is targeting synthetic lethal interactions in SF3B1-mutant cancers and expanding indications into solid tumors like uveal melanoma and breast cancer.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Splicing Modulators | H3 Biomedicine (Eisai), Syros Pharmaceuticals | MDS, AML, CLL | Binding Affinity Assay (Need WT vs. K700E mutant recombinant proteins) |
| Synthetic Lethality / Degraders | Academic Institutes, Biotech Startups | Uveal Melanoma, Breast Cancer | Target Engagement & Knockdown Validation (Need validated siRNA and stable cell lines) |
| Combination Therapies | Clinical Investigators | Refractory Hematological Malignancies | Splicing Alteration Detection (Need high-titer SF3B1 mutant lentiviruses) |